Impact of three different daily doses of vitamin D3 supplementation in healthy schoolchildren and adolescents from North India: a single-blind prospective randomised clinical trial.
Adolescent
Alkaline Phosphatase
/ blood
Calcium
/ blood
Child
Cholecalciferol
/ administration & dosage
Creatinine
/ urine
Dietary Supplements
Female
Humans
Hyperparathyroidism, Secondary
/ blood
India
Male
Parathyroid Hormone
/ blood
Phosphates
/ blood
Prospective Studies
Single-Blind Method
Students
Vitamin D
/ analogs & derivatives
Vitamin D Deficiency
/ blood
Vitamins
/ administration & dosage
25(OH)D 25-hydroxyvitamin D
ALP alkaline phosphatase
IAP Indian Academy of Pediatrics
ICMR Indian Council of Medical Research
IOM Institute of Medicine
PTH parathyroid hormone
UCaCrR urinary calcium:creatinine ratio
VDD vitamin D deficiency
Children and adolescents
Secondary hyperparathyroidism
Vitamin D deficiency
Vitamin D3 supplementation
Journal
The British journal of nutrition
ISSN: 1475-2662
Titre abrégé: Br J Nutr
Pays: England
ID NLM: 0372547
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
entrez:
8
3
2019
pubmed:
8
3
2019
medline:
25
12
2019
Statut:
ppublish
Résumé
In India, there is a lack of information about the adequate daily dose of vitamin D3 supplementation in school children. Hence, we undertook this study to evaluate the adequacy and efficacy of different doses of vitamin D3 in schoolchildren. A total of 1008 vitamin D-deficient (VDD) children, aged 6-16 years with serum 25-hydroxyvitamin D (25(OH)D) levels <50nmol/l, were cluster randomised into three groups (A-344, B-341 and C-232) for supplementation (600, 1000 and 2000 IU daily) of vitamin D3 under supervision for 6 months. Of the 1008 subjects who completed the study, 938 (93 %) were compliant. Baseline and post-supplementation fasting blood and urine samples were evaluated for Ca, phosphates, alkaline phosphatase, 25(OH)D and parathormone and urine Ca:creatinine ratio. The mean age of the subjects was 11·7 (sd 2·4) years, and the overall mean baseline serum 25(OH)D level was 24·3 (SD 9·5)nmol/l. Post-supplementation rise in serum 25(OH)D in compliant group was maximum with 2000 IU (70·0 (SD 30·0)nmol/l), followed by 1000 IU (46·8 (SD 22·5)nmol/l) and 600 IU (36·5 (SD 18·5)nmol/l), and serum 25(OH)D levels of ≥50nmol/l were achieved in 71·5, 81·8 and 92·9 % by groups A, B and C, respectively. Secondary hyperparathyroidism decreased from 31·7 to 8·4 % post-supplementation. Two participants developed hypercalciuria, but none developed hypercalcaemia. Children with VDD benefit maximum with the daily supplementation of 2000 IU of vitamin D3. Whether recommendations of 400 IU/d by Indian Council of Medical Research or 600 IU by Indian Academy of Pediatrics or Institute of Medicine would suffice to achieve vitamin D sufficiency in children with VDD remains debatable.
Identifiants
pubmed: 30843501
pii: S0007114518003690
doi: 10.1017/S0007114518003690
doi:
Substances chimiques
Parathyroid Hormone
0
Phosphates
0
Vitamins
0
Vitamin D
1406-16-2
Cholecalciferol
1C6V77QF41
25-hydroxyvitamin D
A288AR3C9H
Creatinine
AYI8EX34EU
Alkaline Phosphatase
EC 3.1.3.1
Calcium
SY7Q814VUP
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM